Top

Published in:

28-09-2023 | Cytostatic Therapy | Peritoneal Surface Malignancy

Results of the First Phase I PIPAC Trial in the United States: Braving the Storm

Authors: Beatrice J. Sun, MD, Byrne Lee, MD, FACS, FSSO

Published in: Annals of Surgical Oncology | Issue 13/2023

Excerpt

The peritoneum is a common site of metastasis in colorectal and appendiceal cancers and is associated with poor prognosis. Treatment of peritoneal metastases (PM) is challenging and while cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is an option for select patients with PM, those with unresectable high burden of peritoneal disease are limited to systemic options. Unfortunately, chemotherapy has demonstrated poor efficacy and lower overall survival (OS) in the treatment of PM when compared with metastases of non-peritoneal sites, and thus additional treatment options are desperately needed.¹ …

Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17(12):1709–19. https://doi.org/10.1016/S1470-2045(16)30500-9.CrossRefPubMed

Solass W, Herbette A, Schwarz T, et al. Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept. Surg Endosc. 2012;26(3):847–52. https://doi.org/10.1007/s00464-011-1964-y.CrossRefPubMed

Solass W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21(2):553–9. https://doi.org/10.1245/s10434-013-3213-1.CrossRefPubMed

Raoof M, Whelan RL, Sullivan KM, et al. Safety and efficacy of oxaliplatin pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in colorectal and appendiceal cancer with peritoneal metastases: results of a multicenter phase I trial in the USA. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-13941-2.CrossRefPubMedPubMedCentral

Rovers KP, Wassenaar ECE, Lurvink RJ, et al. Pressurized intraperitoneal aerosol chemotherapy (oxaliplatin) for unresectable colorectal peritoneal metastases: a multicenter, single-arm, phase II trial (CRC-PIPAC). Ann Surg Oncol. 2021;28(9):5311–26. https://doi.org/10.1245/s10434-020-09558-4.CrossRefPubMed

Kim G, Tan HL, Sundar R, et al. PIPAC-OX: a phase I study of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy in patients with peritoneal metastases. Clin Cancer Res. 2021;27(7):1875–81. https://doi.org/10.1158/1078-0432.CCR-20-2152.CrossRefPubMed

Taibi A, Sgarbura O, Hübner M, et al. Feasibility and safety of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy with or without intraoperative intravenous 5-fluorouracil and leucovorin for colorectal peritoneal metastases: a multicenter comparative cohort study. Ann Surg Oncol. 2022;29(8):5243–51. https://doi.org/10.1245/s10434-022-11577-2.CrossRefPubMed

Sgarbura O, Hübner M, Alyami M, et al. Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: a multicenter study. Eur J Surg Oncol. 2019;45(12):2386–91. https://doi.org/10.1016/j.ejso.2019.05.007.CrossRefPubMed

Marin D, Catalano C, Baski M, et al. 64-Section multi-detector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlation with histopathological findings. Abdom Imaging. 2010;35(6):694–700. https://doi.org/10.1007/s00261-008-9464-9.CrossRefPubMed

10.

Dromain C, Leboulleux S, Auperin A, et al. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging. 2008;33(1):87–93. https://doi.org/10.1007/s00261-007-9211-7.CrossRefPubMed

11.

Goéré D, Glehen O, Quenet F, et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol. 2020;21(9):1147–54. https://doi.org/10.1016/S1470-2045(20)30322-3.CrossRefPubMed

12.

Graversen M, Detlefsen S, Ainsworth AP, et al. Treatment of peritoneal metastasis with pressurized intraperitoneal aerosol chemotherapy: results from the prospective PIPAC-OPC2 study. Ann Surg Oncol. 2023;30(5):2634–44. https://doi.org/10.1245/s10434-022-13010-0.CrossRefPubMed

13.

Ploug M, Graversen M, Pfeiffer P, Mortensen MB. Bidirectional treatment of peritoneal metastasis with pressurized intraperitoneal aerosol chemotherapy (PIPAC) and systemic chemotherapy: a systematic review. BMC Cancer. 2020;20:105. https://doi.org/10.1186/s12885-020-6572-6.CrossRefPubMedPubMedCentral

14.

Hübner M, Alyami M, Villeneuve L, et al. Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: technical aspects and treatment protocols. Eur J Surg Oncol. 2022;48(4):789–94. https://doi.org/10.1016/j.ejso.2021.10.028.CrossRefPubMed

15.

Nowacki M, Alyami M, Villeneuve L, et al. Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: an international survey study. Eur J Surg Oncol. 2018;44(7):991–6. https://doi.org/10.1016/j.ejso.2018.02.014.CrossRefPubMed

16.

Odendahl K, Solass W, Demtröder C, et al. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Eur J Surg Oncol. 2015;41(10):1379–85. https://doi.org/10.1016/j.ejso.2015.06.001.CrossRefPubMed

17.

Graversen M, Detlefsen S, Bjerregaard JK, Fristrup CW, Pfeiffer P, Mortensen MB. Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Ther Adv Med Oncol. 2018;10:1758835918777036. https://doi.org/10.1177/1758835918777036.CrossRefPubMedPubMedCentral

Title: Results of the First Phase I PIPAC Trial in the United States: Braving the Storm
Authors: Beatrice J. Sun, MD
Byrne Lee, MD, FACS, FSSO
Publication date: 28-09-2023
Publisher: Springer International Publishing
Keywords: Cytostatic Therapy
Colorectal Cancer
Colorectal Cancer
Published in: Annals of Surgical Oncology / Issue 13/2023
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-023-14353-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Results of the First Phase I PIPAC Trial in the United States: Braving the Storm

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 13/2023

ASO Visual Abstract: Quantitative Evaluation of Periodontitis for Predicting the Occurrence of Postoperative Pneumonia after Oncologic Esophagectomy

ASO Visual Abstract: Postoperative Outcomes and Quality of Life After Left Thoracoabdominal Esophagogastrectomy—Contrasting Esophagogastrostomy with Esophagojejunostomy

ASO Author Reflections: Upfront Surgery Followed by Adjuvant Therapy: An Option for IIIA-N2 Non-small Cell Lung Cancer

ASO Visual Abstract: Radiomics Nomogram with Added Nodal Features Improves Treatment Response Prediction in Locally Advanced Esophageal Squamous Cell Carcinoma—A Multicenter Study

ASO Visual Abstract: Novel Non-Duct-to-Mucosa Pancreaticojejunostomy Reconstruction After Pancreaticoduodenectomy—Focus on the Occurrence of Post-Pancreatectomy Hemorrhage and Intra-Abdominal Abscess

Discordant Breast and Axillary Pathologic Response to Neoadjuvant Chemotherapy